Driehaus Capital Management LLC Zai Lab LTD Transaction History

Driehaus Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$27.77 - $64.4 $247,541 - $574,061	-8,914 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$54.9 - $105.21 $489,378 - $937,841	8,914 New	8,914 $560,000
Q3 2021 Nov 15, 2021	SELL	$105.0 - $178.37 $26.3 Million - $44.7 Million	-250,349 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$125.11 - $180.0 $6.8 Million - $9.79 Million	54,362 Added 27.74%	250,349 $44.3 Million
Q1 2021 May 17, 2021	SELL	$126.27 - $191.71 $18.1 Million - $27.4 Million	-143,047 Reduced 42.19%	195,987 $26.2 Million
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $27.8 Million - $45.9 Million	339,034 New	339,034 $45.9 Million
Q4 2017 Feb 14, 2018	SELL	$21.23 - $34.09 $771,816 - $1.24 Million	-36,355 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$27.0 - $31.11 $981,585 - $1.13 Million	36,355	36,355 $982,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.95B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.